Bioqual (BIOQ) Aktie Kurs
Bioqual Kurs
Omsætningen er vokset med 4,1 % om året de seneste 22 år til 39,95 Mio. USD. Indtjening pr. aktie er faldet med 1,7 % om året de seneste 20 år. Bioquals nettoavance ligger på -10,4 %, ned fra 8,0 % for flere år siden. Bioqual har i øjeblikket et direkteafkast på omkring 1,52 %. Udlodningsandelen er omkring 54 % af indtjeningen. Udbyttet er vokset med 8,3 % om året de seneste 19 år.
Bioqual aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Bioqual aktie og aktieanalyse
Hyppigt stillede spørgsmål om Bioqual-aktien
The business model of Bioqual Inc is to provide contract research services to biotechnology and pharmaceutical companies, government agencies, and academic institutions. Bioqual specializes in preclinical and clinical research, including animal model development, in vitro testing, and regulatory compliance. Through collaboration with clients, Bioqual aims to advance the development of drugs, vaccines, and therapeutics, ultimately contributing to the improvement of human and animal health. With its expertise and state-of-the-art facilities, Bioqual Inc has established itself as a trusted partner in the biomedical research industry.
Bioqual Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Bioqual Inc in the market include Company A, Company B, and Company C. These companies operate in the same industry and offer similar products and services to Bioqual Inc. Their competitive presence challenges Bioqual Inc's market position and drives innovation within the industry. Maintaining a competitive edge is crucial for Bioqual Inc to attract and retain customers, expand its market share, and achieve long-term success. As Bioqual Inc continues to navigate its way in the market, it recognizes the importance of monitoring and adapting to the strategies and offerings of its key competitors.
Bioqual Inc. is a reputable company with a rich history and background. Established in [year], Bioqual Inc. has been a leading player in the [industry] sector. The company specializes in [specific products/services] and has built a strong reputation for its commitment to innovation, quality, and customer satisfaction. With a team of experienced professionals and state-of-the-art facilities, Bioqual Inc. has consistently delivered outstanding results and garnered recognition for its contributions to [industry]. Over the years, Bioqual Inc. has expanded its presence globally and continues to be a trusted name in the [industry] market, providing sustainable solutions and driving advancements in [industry].
Bioqual Inc has achieved several significant milestones over the years. The company has successfully gained recognition as a leading biomedical research organization, specializing in preclinical and clinical testing services. Notably, Bioqual Inc has garnered a strong reputation for its contributions to drug development, infectious disease research, and vaccine testing. The company has also established numerous strategic partnerships with pharmaceutical and biotech companies, academia, and government agencies. Furthermore, Bioqual Inc has consistently demonstrated exceptional scientific expertise, state-of-the-art facilities, and a commitment to quality, making it a trusted name in the industry.
Bioqual Inc is primarily present in the United States.
Bioqual Inc represents a commitment to excellence in the field of biomedical research. With a strong emphasis on animal modeling and preclinical testing services, Bioqual is dedicated to paving the way for breakthrough discoveries in healthcare and life sciences. The company's corporate philosophy revolves around comprehensive expertise, innovative solutions, and ensuring the highest standards of animal welfare. By providing state-of-the-art facilities and a team of skilled professionals, Bioqual strives to support scientific advancements and contribute to the development of novel therapies and vaccines. With a focus on quality, reliability, and integrity, Bioqual Inc is trusted by leading pharmaceutical and biotechnology companies worldwide.
Omregnet til den aktuelle valutakurs handles Bioqual-aktien til 29,36 EUR (33,00 USD).
Bioqual Inc is a US-based company specializing in providing research services and products for the life sciences, pharmaceuticals, and biotechnology industries. The company was founded in 1981 and has been offering innovative solutions to its customers since then.
-omsætningen for Bioqual er 39,95 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
-overskuddet for Bioqual er -4,17 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Bioqual er i øjeblikket -7,08. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Bioqual-aktien.
Pris-til-salgs-forholdet (P/S) for Bioqual er i øjeblikket 0,74. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Bioqual-aktien.
AlleAktien-kvalitetsscore for Bioqual er 1/10.
ISIN for Bioqual er US09065J1016. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
Tickeren for Bioqual er BIOQ. Tickersymbolet bruges til at handle Bioqual-aktier på børsen.
Bioqual aktie
Bioqual FIGI
Alle fundamentale data om Bioqual i deep dive
Vores aktieanalyse af Bioqual-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Bioqual. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: